Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma
Expert Rev Respir Med. 2021 Nov 16. doi: 10.1080/17476348.2021.2005585. Online ahead of print.ABSTRACTINTRODUCTION: Fixed-dose long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) combinations and add-on therapies as needed are the mainstay for maintenance therapy in asthma. However, more than 40% of patients have an inadequately controlled disease. The development of triple fixed-dose combinations consisting of long-acting muscarinic antagonist (LAMA)/LABA/ICS has paved the way for a new approach to reach therapeutic goals of an optimal control of symptoms and an effective prevention of future exacerbations.AREAS...
Source: Expert Review of Respiratory Medicine - November 16, 2021 Category: Respiratory Medicine Authors: Luis P érez de Llano Elsa Naval Natalia Mej ía Javier Dom ínguez-Ortega Source Type: research
Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions
Expert Opin Drug Saf. 2021 Nov 1. doi: 10.1080/14740338.2022.1999926. Online ahead of print.ABSTRACTINTRODUCTION: Inhaled corticosteroids (ICS) are known to increase the risk of systemic and local adverse effects, especially with high doses and long term use. Hence, considerable resources are invested to improve pharmacokinetic/pharmacodynamic (PK/PD) properties of ICS, effective delivery systems and novel combination therapies to enhance the risk-to-benefit ratio of ICS.AREAS COVERED: There is an unmet need for new solutions to achieve optimal clinical outcomes with minimal dose of ICS. This paper gives an overview of nov...
Source: Expert Opinion on Drug Safety - November 1, 2021 Category: Drugs & Pharmacology Authors: Piotr Damia ński Grzegorz Kardas Micha ł Panek Piotr Kuna Maciej Kupczyk Source Type: research
The possibility of short ‐term hypothalamic‐pituitary‐adrenal axis suppression with high‐volume, high‐dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis
ConclusionsHigh-volume 2 mg twice daily sinonasal mometasone irrigations did not cause HPA axis suppression in a representative sample of patients with refractory CRS post-FESS with normal baseline cortisol levels. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - September 27, 2021 Category: Allergy & Immunology Authors: Hannah J. Brown,
Pete S. Batra,
Michael Eggerstedt,
Ashwin Ganti,
Peter Papagiannopoulos,
Bobby A. Tajudeen Tags: ORIGINAL ARTICLE Source Type: research
Long ‐acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study
ConclusionsLYR-210 is the first implantable sinonasal treatment to achieve up to 24 weeks of benefit from a single administration in surgically naive CRS patients with and without nasal polyps. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - September 18, 2021 Category: Allergy & Immunology Authors: Anders Cervin,
Joanne Rimmer,
Agnieszka Wrobel,
Yogen Abelak,
Lindsay Brayton,
Yina Kuang Tags: ORIGINAL ARTICLE Source Type: research
Inhaled Budesonide vis- à-vis Inhaled Mometasone in Chinese Children with Mild Persistent Asthma: A Single-Center, Retrospective Study
Conclusions: Although both drugs showed improvement in the quality of life of asthmatic children with manageable treatment-emergent adverse effects, the improvement was augmented in MF-treated children.Level of Evidence: The level of evidence was III.Technical Efficacy Stage: The technical efficacy stage was 4.Pharmacology (Source: Pharmacology)
Source: Pharmacology - September 9, 2021 Category: Drugs & Pharmacology Source Type: research
Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses
CONCLUSION: The XTreoTM MF matrices provided targeted and efficient dosing to local sinus tissues that was superior to INCS. Sustained drug release was confirmed both in vitro and in vivo. The novel XTreoTM technology may provide precisely tuned, long-lasting drug delivery to sinus tissues with a single treatment.PMID:34463546 | DOI:10.1177/19458924211039197 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 31, 2021 Category: ENT & OMF Authors: Changcheng You Ling-Fang Tseng Alexander Pappas Danny Concagh Yina Kuang Source Type: research
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
CONCLUSIONS: One time a day, single-inhaler, high-dose MF/IND reduced asthma exacerbations and improved lung function versus two times a day, high-dose FLU/SAL in patients with inadequately controlled asthma. Similarly, improved outcomes were seen with one time a day, medium-dose MF/IND and two times a day, high-dose FLU/SAL, but at a lower ICS dose.PMID:34452934 | DOI:10.1136/bmjresp-2020-000819 (Source: Respiratory Care)
Source: Respiratory Care - August 28, 2021 Category: Respiratory Medicine Authors: Kenneth Chapman Richard van Zyl-Smit Jorge Maspero Huib A M Kerstjens Yasuhiro Gon Motoi Hosoe Ana-Maria Tanase Abhijit Pethe Xu Shu Peter D'Andrea Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
Complications Associated with PROPEL Mometasone Furoate Bioabsorbable Drug-eluting Sinus Stents From 2012 to 2020
CONCLUSIONS: PROPEL sinus stents have been shown to be effective in preventing sinus outflow obstruction after functional endoscopic sinus surgery. Both adverse events to patients and device malfunctions are reported infrequently. A more comprehensive understanding of rare postmarket complications seen with PROPEL sinus stents may further aid informed decision-making regarding their usage.PMID:34342518 | DOI:10.1177/19458924211035641 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 3, 2021 Category: ENT & OMF Authors: Viraj N Shah Luke J Pasick Daniel A Benito Michael K Ghiam Christine D'Aguillo Source Type: research
